Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature

By sjmartinez • January 2, 2025

Barghi A, Noveir SD, Mainwaring W, Milani-Nejad N, Bernet L. Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature. Int J Dermatol. 2024 Dec 30. doi: 10.1111/ijd.17626. Epub ahead of print. PMID: 39739856.

Tags: bullous pemphigoid, Dermatology, DGSOM Student, Dupilumab, eosinophilic annular erythema, immune checkpoint inhibitor, pembrolizumab, Publications

Whole genome sequence of the syntrophic benzoate-degrading bacterium, Syntrophus buswellii DSM 102354T

Gunsalus RP, Humm E, Cook L, Wofford NQ, James KL, Pellegrini M, Morselli M, Ha SM, McInerney MJ. Whole genome sequence of the syntrophic benzoate-degrading[...]

Squamous Eccrine Ductal Carcinoma: A Comprehensive Review of the Clinicopathologic Features and Management in 27 Cases

Gudino-Rosales S, Lilley CM, Gates G, Kneiber D. Squamous Eccrine Ductal Carcinoma: A Comprehensive Review of the Clinicopathologic Features and Management in 27 Cases. Cureus.[...]

Brodalumab: Seven-Year US Pharmacovigilance Report

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]